Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Dec 17, 2024

BUY
$4.05 - $5.43 $41,310 - $55,386
10,200 New
10,200 $53.2 Million
Q1 2024

Dec 04, 2024

BUY
$3.25 - $5.27 $7,150 - $11,593
2,200 New
2,200 $9.97 Million

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.55B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Catalyst Funds Management Pty LTD Portfolio

Follow Catalyst Funds Management Pty LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Catalyst Funds Management Pty LTD, based on Form 13F filings with the SEC.

News

Stay updated on Catalyst Funds Management Pty LTD with notifications on news.